AI assistant
NYRADA INC. — Investor Presentation 2021
Sep 12, 2021
65469_rns_2021-09-12_cd8ef883-0c8a-4810-845c-eb6e8b2a779b.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [596 x 114] intentionally omitted <==
Presentation to ASX Small and Mid-Cap Conference
Sydney, 13 September 2021: Nyrada Inc (ASX: NYR) is pleased to provide to shareholders and the market generally the corporate presentation that will be used by Nyrada CEO, James Bonnar at the ASX Small and Mid-Cap Conference on Tuesday 14 September, at 11.00am (AEST).
Mr Bonnar will provide an update on Nyrada’s Cholesterol-Lowering and Brain Injury drug development programs, as well as the vision, strategy, and market opportunity.
To register for the conference, please use the following link: https://www2.asx.com.au/investors/investment-tools-and-resources/events/smid
About Nyrada Inc
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.
www.nyrada.com
Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.
Investor & Corporate Enquiries: Company Secretary: Laura Vize David Franks Investor Relations Manager T: 02 8072 1400 T: 0417 026 056 E: [email protected] E: [email protected]
Media Enquiries:
Catherine Strong Citadel-MAGNUS T: 02 8234 0111
Page 1
Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072
ARBN 625 401 818
==> picture [596 x 114] intentionally omitted <==
Forward-Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.
Page 2 ARBN 625 401 818
Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072
==> picture [112 x 113] intentionally omitted <==
==> picture [89 x 89] intentionally omitted <==
1
==> picture [89 x 89] intentionally omitted <==
2
==> picture [89 x 89] intentionally omitted <==
==> picture [28 x 29] intentionally omitted <==
==> picture [28 x 29] intentionally omitted <==
We aim to deliver novel treatments for diseases
==> picture [28 x 28] intentionally omitted <==
There is an unmet clinical need ; or Current treatments are suboptimal
==> picture [28 x 29] intentionally omitted <==
==> picture [28 x 29] intentionally omitted <==
3
==> picture [89 x 89] intentionally omitted <==
Two lead
programs:
Cholesterol-Lowering Program Oral PCSK9 inhibitor to be used alone, or in combination with a statin
- Key value inflection point end of Phase I
Brain Injury Program Intravenous and intranasal drug to help people who sustain a traumatic brain injury (TBI) or suffer a stroke
- Key value inflection point at end of Phase II
Innovative Treatments
Best-in-Class / First-Line
Clinical Need
Market Potential
Strong Patent Protection Commercialise Early
4
==> picture [89 x 89] intentionally omitted <==
==> picture [250 x 250] intentionally omitted <==
Cholesterol-Lowering Animation
5
==> picture [89 x 89] intentionally omitted <==
==> picture [148 x 148] intentionally omitted <==
==> picture [284 x 138] intentionally omitted <==
Oral PCSK9 treatment
Costeffective
Convenient for patient
Small molecule PCSK9 inhibitor overcomes longstanding challenge of oral treatment
Can be combined with statin to deliver a first ever single pill PCSK9/statin treatment
6
Program Results
==> picture [89 x 89] intentionally omitted <==
Impressive Cholesterol Lowering Performance[1]
-
❑ NYX-PCSK9i reduced cholesterol by almost half vs. Lipitor[® ] alone (27%) ❑ Reduced cholesterol by 65% when dosed with Lipitor[®]
-
❑ Equivalent cholesterol reduction to injectable PSCK9 inhibitor Praluent[®]
-
❑ Well-tolerated, no adverse effects
Strong Patent Position
-
❑ US patent granted for Nyrada’s PCSK9 inhibitor technology
-
❑ Development of 2[nd ] generation compounds well advanced
1 In vivo studies were conducted using a specialised mouse model, APOE*3-Leiden.CETP, specifically generated to possess human-like characteristics concerning cholesterol metabolism and cardiovascular health. The model has been used for over 170 drug intervention studies by the pharmaceutical industry over the last 15 years.
7
==> picture [89 x 89] intentionally omitted <==
In vivo study – June 2021
==> picture [361 x 257] intentionally omitted <==
| Table 1. Percentage change in total cholesterol when compared to vehicle control. There were 8 mice in each experimental group. P-values are shown in brackets, with significant p-values in bold. % Difference in plasma cholesterol versus vehicle control (p-value) Time (days) 7 14 21 28 35 NYX-PCSK9i -18% (0.066) -24%(0.002) -31%(0.001) -37%(<0.001) -46%(<0.001) Lipitor -13% (0.275) -15% (0.077) -31%(0.001) -31%(<0.001) -27%(<0.001) NYX-PCSK9i + Lipitor -33%(<0.001) -49%(<0.001) -56%(<0.001) -57%(<0.001) -65%(<0.001) |
|
|---|---|
==> picture [144 x 72] intentionally omitted <==
8
==> picture [89 x 89] intentionally omitted <==
==> picture [257 x 257] intentionally omitted <==
Brain Injury Solution Animation
9
Brain Injury Problem
==> picture [89 x 89] intentionally omitted <==
-
2.8 million traumatic brain injuries (TBI) in US (2017)[1]
-
4.1 million TBIs globally (2020)[2]
-
[~] 800,000 strokes annually
-
in US[3]
==> picture [55 x 170] intentionally omitted <==
-
Treatment options limited to neurosurgery and supportive care
-
One drug class for stroke (Suitable for less than 15% of patients)
-
No FDA approved TBI drug
==> picture [63 x 170] intentionally omitted <==
-
High mortality
-
Severe life-long disability
-
High ongoing healthcare cost
==> picture [117 x 88] intentionally omitted <==
==> picture [117 x 88] intentionally omitted <==
==> picture [117 x 88] intentionally omitted <==
==> picture [250 x 12] intentionally omitted <==
----- Start of picture text -----
Minutes Hours
----- End of picture text -----
==> picture [32 x 14] intentionally omitted <==
----- Start of picture text -----
Days
----- End of picture text -----
Initial injury size
Final injury size
-
1 Traumatic Brain Injury–Related Deaths by Race/Ethnicity, Sex, Intent, and Mechanism of Injury — United States, 2000–2017, Nov 22, 2019, US CDC, Jill Daugherty, PhD1; Dana Waltzman, PhD; Kelly Sarmiento, MPH; Likang Xu, MD: https://www.cdc.gov/mmwr/volumes/68/wr/mm6846a2.htm
-
2 Total TBIs in US, Germany, France, Italy, Spain, UK and Japan, Traumatic Brain Injury, Market Insight, Epidemiology and Market Forecast, DelveInsight, published January 2021. 3 US Centers for Disease Control and Prevention: https://www.cdc.gov/stroke/index.htm
10
==> picture [89 x 89] intentionally omitted <==
==> picture [23 x 24] intentionally omitted <==
==> picture [454 x 261] intentionally omitted <==
----- Start of picture text -----
Primary Secondary Disability
Injury Injury Level
Hours Days Weeks Months
----- End of picture text -----
11
==> picture [89 x 89] intentionally omitted <==
Proof of Concept
Optimised Compound
International Collaboration
-
❑ NYX-1010 showed excellent potency and blood-brain barrier penetration to reach areas of the brain damaged after TBI[1]
-
❑ NYR-BI01 more potent and drug-like compound than its predecessor NYX-1010[1]
-
❑ Collaboration secured with the world-leading scientific teams at Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney
-
❑ Strategic alignment: TBI occurs in 1 in 25 military service members ❑ NYR-BI01 selected for efficacy studies to be run at WRAIR
==> picture [14 x 17] intentionally omitted <==
----- Start of picture text -----
1
----- End of picture text -----
12
==> picture [89 x 89] intentionally omitted <==
==> picture [19 x 20] intentionally omitted <==
==> picture [19 x 20] intentionally omitted <==
==> picture [19 x 20] intentionally omitted <==
==> picture [341 x 266] intentionally omitted <==
13
==> picture [89 x 89] intentionally omitted <==
==> picture [91 x 124] intentionally omitted <==
==> picture [89 x 124] intentionally omitted <==
==> picture [91 x 124] intentionally omitted <==
==> picture [90 x 124] intentionally omitted <==
==> picture [90 x 124] intentionally omitted <==
==> picture [91 x 124] intentionally omitted <==
==> picture [16 x 17] intentionally omitted <==
==> picture [16 x 17] intentionally omitted <==
14
==> picture [89 x 89] intentionally omitted <==
CY 2021 CY 2022
==> picture [13 x 14] intentionally omitted <==
==> picture [13 x 14] intentionally omitted <==
15
[email protected] www.nyrada.com
==> picture [89 x 89] intentionally omitted <==
==> picture [219 x 219] intentionally omitted <==
Brain Injury Solution Animation
==> picture [214 x 214] intentionally omitted <==
Cholesterol-Lowering Animation
==> picture [49 x 48] intentionally omitted <==
==> picture [40 x 40] intentionally omitted <==
==> picture [40 x 40] intentionally omitted <==
@nyrada_inc
@nyrada_inc
ASX: NYR
16